Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Etohexadiol (also known as ethohexadiol, 2-ethyl-1,3-hexanediol) is a small molecule ectoparasiticide and insect repellent that was marketed under the names "6-12" and "Rutgers 612". It belongs to the class of fatty alcohols and is an aliphatic diol. Etohexadiol was widely used topically as an insect repellent but its use in the United States was discontinued in 1991 after studies showed it caused developmental defects in animals[1][2][3]. The compound has also been used industrially as a solvent, chelating agent, plasticizer component in cosmetics and other formulations[3][7]. Its mechanism of action as an insect repellent likely involves disruption of biological membranes and proteins in insects[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ethohexadiol.